322
Views
34
CrossRef citations to date
0
Altmetric
Urology

Tamsulosin as adjunctive treatment after shockwave lithotripsy in patients with upper urinary tract stones: A systematic review and meta-analysis

, , &
Pages 425-432 | Received 03 Jun 2010, Accepted 29 Jul 2010, Published online: 17 Nov 2010
 

Abstract

Objective. This study aimed to evaluate the efficacy of tamsulosin as an α1-blocker in the treatment of the renal and ureteral stones after shockwave lithotripsy (SWL). Material and methods. Relevant randomized controlled trials were identified by electronic and document searches of MEDLINE, EMBASE, the Chinese Biomedical Disk and the Cochrane Central Register of Controlled Trials until April 2010. No language restriction was applied. Trials were included if patients were randomized to receive either tamsulosin or standard therapy with or without placebo after SWL. The main outcome was the stone clearance rate. Two reviewers independently assessed trial quality and extracted data. Meta-analysis was conducted with Review Manager (RevMan) version 5.0. Results. Fifteen studies involving 1326 subjects met the inclusion criteria. Study duration ranged from 2 weeks to 3 months. The pooled analysis showed a 24% [risk ratio (RR) = 1.24, 95% confidence interval (CI) 1.12 to 1.37] improvement in stone clearance tamsulosin. According to stone locations (renal, upper ureteral and lower ureteral), the pooling effects of tamsulosin were analysed, with a higher expulsion rate obtained than control (RR = 1.38, 1.83, 1.43, and 95% CI 1.17 to 1.61, 1.20 to 2.78, 1.13 to 1.81, respectively). Tamsulosin 0.4 mg had a high possibility of achieving successful outcome (RR = 1.29, 95% CI 1.14 to 1.47). In addition, a shorter expulsion time, lower analgesic requirements, fewer colic episodes and adverse effects were observed. Conclusions. Tamsulosin is a safe and effective therapy for renal and ureteral stones after SWL. Further, high-quality randomized trials are necessary to confirm its efficacy.

Acknowledgements

The authors would like to thank staff and colleagues in the Chinese Cochrane Centre for their help and support.

Declaration of interest: The authors report no conflicts of interest. The authors alone are responsible for the content and writing of the paper.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.